Skip to main content
Erschienen in: Abdominal Radiology 3/2018

10.07.2017

Preoperative CT in patients with surgically resectable pancreatic adenocarcinoma: does the time interval between CT and surgery affect survival?

verfasst von: Gerard M. Healy, C. E. Redmond, S. Murphy, H. Fleming, A. Haughey, R. Kavanagh, N. Swan, K. C. Conlon, D. E. Malone, E. R. Ryan

Erschienen in: Abdominal Radiology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The preoperative imaging-to-surgery time interval (ISI) influences the risk of unexpected progression (UP) found at surgery for pancreatic adenocarcinoma. We aimed to assess whether ISI influences disease recurrence and/or survival.

Methods and materials

A single-institution, ethics board-approved retrospective analysis of all patients who underwent attempted resection of pancreatic (PDAC) or periampullary adenocarcinoma (AmpAC) between 1st January 2010 and 31st December 2015 was performed. All patients underwent preoperative abdominal computed tomography (CT). Exclusion criteria were borderline resectable disease and neoadjuvant chemo/radiotherapy. Patients were followed up until 30th June 2016. The population was divided into ISI ≥/<25 days. Kaplan–Meier and Cox regression survival analyses were performed.

Results

239 patients underwent surgical exploration. UP was found in 29 (12.1%) and these patients had longer ISI (median 46 vs. 29 days, p < 0.05). When intention-to-treat analysis was performed, there was no difference in overall survival (OS) between patients with ISI ≥/<25. In those who underwent resection, ISI did not influence disease-free survival (DFS) or OS for PDAC (n = 174). For AmpAC (n = 36), ISI ≥ 25 days was associated with longer OS (p < 0.05) but did not influence DFS. Longer ISI was independently associated with improved OS on regression analysis for AmpAC.

Conclusion

Performing surgery for resectable pancreatic adenocarcinoma within 25 days of abdominal CT reduces the chance of UP but does not confer a survival benefit. For those who undergo resection of AmpAC, a longer ISI was associated with longer OS. This probably represents a more biologically indolent disease in this cohort.
Literatur
2.
Zurück zum Zitat Feldman M, Gandhi N (2016) Imaging evaluation of pancreatic cancer. Surg Clin N Am 96(6):1235–1256CrossRefPubMed Feldman M, Gandhi N (2016) Imaging evaluation of pancreatic cancer. Surg Clin N Am 96(6):1235–1256CrossRefPubMed
3.
Zurück zum Zitat Hishinuma S, Ogata Y, Tomikawa M, et al. (2006) Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 10:511–518CrossRefPubMed Hishinuma S, Ogata Y, Tomikawa M, et al. (2006) Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 10:511–518CrossRefPubMed
4.
Zurück zum Zitat Tempero M, Malafa M, Behrmen S, et al. (2014) Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 12(8):1083–1093CrossRefPubMed Tempero M, Malafa M, Behrmen S, et al. (2014) Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 12(8):1083–1093CrossRefPubMed
5.
Zurück zum Zitat Raman S, Chen Y, Fishman E (2015) Cross-sectional imaging and the role of positron emission tomography in pancreatic cancer evaluation. Semin Oncol 42:40–58CrossRefPubMed Raman S, Chen Y, Fishman E (2015) Cross-sectional imaging and the role of positron emission tomography in pancreatic cancer evaluation. Semin Oncol 42:40–58CrossRefPubMed
7.
Zurück zum Zitat Allen V, Gurusamy K, Takwoingi Y, Kalia A, Davidson B (2016) Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev 7:CD009323 Allen V, Gurusamy K, Takwoingi Y, Kalia A, Davidson B (2016) Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev 7:CD009323
8.
Zurück zum Zitat Raman S, Reddy S, Weiss M, et al. (2015) Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer. Am J Radiol 204:W37–W42 Raman S, Reddy S, Weiss M, et al. (2015) Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer. Am J Radiol 204:W37–W42
9.
Zurück zum Zitat Yu J, Blackford A, dal Molin M, Wolfgang C, Goggins M (2015) Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut 64(11):1783–1789CrossRefPubMedPubMedCentral Yu J, Blackford A, dal Molin M, Wolfgang C, Goggins M (2015) Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut 64(11):1783–1789CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Ahn S, Choi S, Kim HS (2016) Time to progression of pancreatic cancer: evaluation with multi-detector computed tomography. J Gastrointest Cancer 48(2):164–169CrossRef Ahn S, Choi S, Kim HS (2016) Time to progression of pancreatic cancer: evaluation with multi-detector computed tomography. J Gastrointest Cancer 48(2):164–169CrossRef
11.
Zurück zum Zitat Glant J, Waters J, House M, et al. (2011) Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Surgery 150(4):607–616CrossRefPubMed Glant J, Waters J, House M, et al. (2011) Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Surgery 150(4):607–616CrossRefPubMed
12.
Zurück zum Zitat Sanjeevi S, Ivanics T, Lundell L, et al. (2016) Impact of delay between imaging and treatment in patients with potentially curable pancreatic cancer. Br J Surg 103:267–275CrossRefPubMed Sanjeevi S, Ivanics T, Lundell L, et al. (2016) Impact of delay between imaging and treatment in patients with potentially curable pancreatic cancer. Br J Surg 103:267–275CrossRefPubMed
14.
Zurück zum Zitat Ryan D, Hong T, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371(11):1039–1049CrossRefPubMed Ryan D, Hong T, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371(11):1039–1049CrossRefPubMed
15.
Zurück zum Zitat Tingstedt B, Weitkamper C, Andersson R (2011) Early onset pancreatic cancer: a controlled trial. Ann Gastroenterol 24(3):206–212PubMedPubMedCentral Tingstedt B, Weitkamper C, Andersson R (2011) Early onset pancreatic cancer: a controlled trial. Ann Gastroenterol 24(3):206–212PubMedPubMedCentral
16.
Zurück zum Zitat Kim S, Eads J (2016) Adjuvant and neoadjuvant therapy for resectable pancreatic and periampullary cancer. Surg Clin N Am 96(6):1287–1300CrossRefPubMed Kim S, Eads J (2016) Adjuvant and neoadjuvant therapy for resectable pancreatic and periampullary cancer. Surg Clin N Am 96(6):1287–1300CrossRefPubMed
17.
Zurück zum Zitat Yong L, Lai S, Liang Z, et al. (2016) Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associated with poor patients survival. Oncotarget 7(52):87431–87448CrossRefPubMedPubMedCentral Yong L, Lai S, Liang Z, et al. (2016) Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associated with poor patients survival. Oncotarget 7(52):87431–87448CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Khashram M, Williman J, Hider P, Jones G, Roake J (2016) Systematic review and meta-analysis of factors influencing survival following abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 51(2):203–215CrossRefPubMed Khashram M, Williman J, Hider P, Jones G, Roake J (2016) Systematic review and meta-analysis of factors influencing survival following abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 51(2):203–215CrossRefPubMed
19.
Zurück zum Zitat Johnson B, Khalil M, Blansfield J, et al. (2016) Investigating the prognostic value of KOC (K homology domain containing protein overexpressed in cancer) overexpression after curative intent resection of pancreatic ductal adenocarcinoma. J Gastrointest Cancer 7(6):E113–117 Johnson B, Khalil M, Blansfield J, et al. (2016) Investigating the prognostic value of KOC (K homology domain containing protein overexpressed in cancer) overexpression after curative intent resection of pancreatic ductal adenocarcinoma. J Gastrointest Cancer 7(6):E113–117
20.
Zurück zum Zitat Deshmukh SD, Willmann JK, Jeffrey RB (2010) Pathways of extrapancreatic perineural invasion by pancreatic adenocarcinoma: evaluation with 3D volume-rendered MDCT imaging. AJR Am J Roentgenol 194(3):668–674. doi:10.2214/ajr.09.3285 CrossRefPubMed Deshmukh SD, Willmann JK, Jeffrey RB (2010) Pathways of extrapancreatic perineural invasion by pancreatic adenocarcinoma: evaluation with 3D volume-rendered MDCT imaging. AJR Am J Roentgenol 194(3):668–674. doi:10.​2214/​ajr.​09.​3285 CrossRefPubMed
21.
Zurück zum Zitat Knudsen E, O’Reilly E, Brody J, Witkiewicz A (2016) Genetic diversity of pancreatic ductal adenocarcinoma and opportunities for Precision medicine. Gastroenterology 150(1):48–63CrossRefPubMed Knudsen E, O’Reilly E, Brody J, Witkiewicz A (2016) Genetic diversity of pancreatic ductal adenocarcinoma and opportunities for Precision medicine. Gastroenterology 150(1):48–63CrossRefPubMed
22.
Zurück zum Zitat Anderson J, Wan W, Kaplan B, Myers J, Fields E (2016) Changing paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation. J Gastrointest Oncol 7(6):1004–1010CrossRefPubMedPubMedCentral Anderson J, Wan W, Kaplan B, Myers J, Fields E (2016) Changing paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation. J Gastrointest Oncol 7(6):1004–1010CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Cloyd J, Katz M, Prakash L, et al. (2016) Preoperative therapy and pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a 25-year single institution experience. J Gastrointest Surg 21(1):164–174CrossRefPubMed Cloyd J, Katz M, Prakash L, et al. (2016) Preoperative therapy and pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a 25-year single institution experience. J Gastrointest Surg 21(1):164–174CrossRefPubMed
24.
Zurück zum Zitat Mirkin K, Hollenbeak C, Gusani N, Wong J (2016) Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancer. Am J Surg 214(1):80–88CrossRefPubMed Mirkin K, Hollenbeak C, Gusani N, Wong J (2016) Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancer. Am J Surg 214(1):80–88CrossRefPubMed
25.
Zurück zum Zitat Golcher H, Brunner T, Witzigmann H, et al. (2015) Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol 1911(1):7–16CrossRef Golcher H, Brunner T, Witzigmann H, et al. (2015) Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol 1911(1):7–16CrossRef
26.
Zurück zum Zitat Tachezy M, Gebauer F, Petersen C, et al. (2014) Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA—a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer 14:411. doi:10.1186/1471-2407-14-411 CrossRefPubMedPubMedCentral Tachezy M, Gebauer F, Petersen C, et al. (2014) Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA—a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer 14:411. doi:10.​1186/​1471-2407-14-411 CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Versteijne E, van Eijck CH, Punt CJ, et al. (2016) Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials 17(1):127. doi:10.1186/s13063-016-1262-z CrossRefPubMedPubMedCentral Versteijne E, van Eijck CH, Punt CJ, et al. (2016) Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials 17(1):127. doi:10.​1186/​s13063-016-1262-z CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Tempero M, Malafa M, Al-Hawary M, et al. (2016) Pancreatic adenocarcinoma: NCCN Clinical Practice Guidelines in oncology. Version 2:2016 Tempero M, Malafa M, Al-Hawary M, et al. (2016) Pancreatic adenocarcinoma: NCCN Clinical Practice Guidelines in oncology. Version 2:2016
31.
Zurück zum Zitat Wang X, Yang F, Jin C, Fu D (2014) Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol 20(42):15580–15589CrossRefPubMedPubMedCentral Wang X, Yang F, Jin C, Fu D (2014) Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol 20(42):15580–15589CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Joo I, Lee JM, Lee DH, et al. (2017) Preoperative assessment of pancreatic cancer with FDG PET/MR imaging versus PET/CT Plus contrast-enhanced multidetector CT: a prospective preliminary study. Radiology 282:1149–1159CrossRef Joo I, Lee JM, Lee DH, et al. (2017) Preoperative assessment of pancreatic cancer with FDG PET/MR imaging versus PET/CT Plus contrast-enhanced multidetector CT: a prospective preliminary study. Radiology 282:1149–1159CrossRef
34.
Zurück zum Zitat Chang J, Kundranda M (2017) Novel diagnostic and predictive biomarkers in pancreatic adenocarcinoma. Int J Mol Sci 18(3):667CrossRefPubMedCentral Chang J, Kundranda M (2017) Novel diagnostic and predictive biomarkers in pancreatic adenocarcinoma. Int J Mol Sci 18(3):667CrossRefPubMedCentral
35.
Zurück zum Zitat Pappas S, Christians K, Tolat P, et al. (2014) Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility of futility. HPB 16(1):70–74CrossRefPubMed Pappas S, Christians K, Tolat P, et al. (2014) Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility of futility. HPB 16(1):70–74CrossRefPubMed
Metadaten
Titel
Preoperative CT in patients with surgically resectable pancreatic adenocarcinoma: does the time interval between CT and surgery affect survival?
verfasst von
Gerard M. Healy
C. E. Redmond
S. Murphy
H. Fleming
A. Haughey
R. Kavanagh
N. Swan
K. C. Conlon
D. E. Malone
E. R. Ryan
Publikationsdatum
10.07.2017
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 3/2018
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1254-9

Weitere Artikel der Ausgabe 3/2018

Abdominal Radiology 3/2018 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.